

Child and Adolescent Clinical Psychopharmacology Made Simple

A 12-Hour Home Study Program for Health Professionals | 184-Page Book

Child and Adolescent Clinical Psychopharmacology Made Simple provides succinct and clear information for nurses, behavioral health professionals, pharmacists, and allied health professions on the diagnosis and pharmacologic treatment of children and adolescents with depression, bipolar disorder, anxiety disorders, psychotic disorders, attention-deficit/hyperactivity disorder, autism spectrum disorders, and miscellaneous disorders. Useful patient and caregiver information sheets are provided including dosing and side-effect profiles.

Participants completing this program should be able to identify psychopharmacological treatment of children and adolescents with the following conditions:

1. Depression
2. Bipolar Disorders
3. Anxiety Disorders
4. Psychotic Disorders
5. Attention-Deficit/Hyperactivity Disorder
6. Autism Spectrum Disorders
7. Miscellaneous disorders

CONTINUING EDUCATION



NURSES: Institute for Brain Potential (IBP) is accredited as a provider of continuing nursing education by the **American Nurses Credentialing Center's Commission on Accreditation**.

IBP is approved as a provider of continuing education by the **CA Board of Registered Nursing**, Provider #CEP13896, and by the **FL Board of Nursing**. This program provides 12 contact hours.



COUNSELORS, PSYCHOLOGISTS, SOCIAL WORKERS & MFTs: Institute for Brain Potential is approved by the **American Psychological Association** to sponsor continuing education for psychologists. IBP maintains responsibility for this program and its content. This program provides 12 CE credits.



IBP, Provider #1160, is approved as a provider for continuing education by the **Association of Social Work Boards (ASWB)**, 400 South Ridge Parkway, Suite B, Culpeper, VA 22701. www.aswb.org. ASWB Approval Period: 11/11/14 – 11/11/17. Social workers should contact their regulatory board to determine course approval. Social workers will receive 12 continuing education clock hours for participating in this course.

IBP is approved as a provider of CE by the **FL Board of Psychology**, by the **FL Board of Clinical Social Work, MFT and Mental Health Counseling**, by the **OH CSWMFT Board**, Provider #RCST030801, by the **IL Dept. of Professional Regulation MFT CE Sponsor Program**, #168.000183, and by the **TX State Board of Examiners of MFTs**, Provider #830. This program provides 12 CE hours.

SUBSTANCE ABUSE PROFESSIONALS: Institute for Brain Potential (IBP) is approved by the **NAADAC Approved Education Provider Program**, Provider #102949. IBP is approved by provider by **CCAPP-EL**, Provider Number 4S-09-128-1217. This program provides 12 CEHs.



PHARMACISTS AND PHARMACY TECHNICIANS: IBP is accredited by the **Accreditation Council for Pharmacy Education** as a provider of continuing pharmacy education. This knowledge-based activity is designated for 12 contact hours (1.2 CEUs). UANs: 0492-0000-17-009-H01-P and 0492-0000-17-009-H01-T.



DENTAL PROFESSIONALS: IBP is designated as an Approved PACE Program Provider by the **Academy of General Dentistry (AGD)**. The formal continuing dental education programs of this provider are accepted by the AGD for Fellowship/Mastership and membership maintenance credit. Approval does not imply acceptance by a state or provincial board of dentistry or AGD endorsement. The current term of approval extends from 12/01/14 – 11/30/18. Provider ID# 312413. This program provides 12 hours of CE credit. Subject Code: 557. IBP, Provider #RP-4261, is authorized to confer continuing dental education for Dentists, Dental Hygienists and Dental Assistants by the **Dental Board of California**. IBP is an approved provider with the **FL Board of Dentistry**. This program provides 12 CE hours.

PHYSICAL THERAPISTS: This program is approved by IBP, which is an accredited approver by the **Physical Therapy Board of CA**. IBP is an **IL Dept. of Professional Regulation Approved CE Sponsor** for PTs and PTAs, #216.000210. IBP is recognized by the **NY State Board of Physical Therapy** as an approved sponsor of physical therapy CE. This program provides 12 CE hours.

MASSAGE THERAPISTS: IBP is an approved CE provider by **IL Dept. of Professional Regulation**, #245.000045. This course provides 12 CE hours. This course is approved for 12 hours of "General" CE Credit by the **FL Board of Massage Therapy**.

SPEECH-LANGUAGE PATHOLOGISTS: IBP is an approved provider by the **CA SLPAB**, # PDP247. This program provides 12 CE hours.

RESPIRATORY CARE PROFESSIONALS: RCPs in New York receive 12 hours of Category III credit through IBP's accreditation by the **ANCC**. IBP is approved by the **CA Board of Registered Nursing**, #CEP13896, and as such, its CE offerings are accepted by **Respiratory Care Board of CA**. This program provides 12 CE hours.

Initial Release Date: 02/04/2017 Expiration Date: 02/04/2020 Content Level: Intermediate

Issues in Psychopharmacological Treatment of Children and Adolescents

- Diagnosing and treating children and adolescents
- Informed consent and addressing parental concerns
- Medications and the media
- Drug research and outcome studies
- Medication metabolism in young clients
- Approved drugs and off label use
- Attitudes and realities

Depressive Disorders

- Diagnostic issues
- Symptoms of major depression in children
- Indications of bipolar disorder
- Efficacy of antidepressants
- Comparing SSRIs, SNRIs, SRIs, NDRIs and Atypicals
- Common side effects of each type
- Antidepressants and suicidality
- Treatment of depressive subtypes
- Medication discontinuation and relapse prevention

Bipolar Disorders

- Diagnostic issues
- Signs and symptoms of early-onset mania
- Differentiating bipolar disorder from ADHD
- Bipolar disorder combined with ADHD
- Bipolar disorder combined with anxiety disorders
- Neurobiology of bipolar disorder
- Psychopharmacology: mood stabilizers and anticonvulsants
- Guidelines for pharmacological treatment
- Mania, depression and manic switching
- Doses and side effects
- Relapse prevention
- Interactions with drugs commonly used in pediatrics

Anxiety Disorders

- Obsessive-compulsive disorder
- Panic disorders
- Social phobia
- Specific phobias
- Generalized anxiety
- Posttraumatic stress disorder
- Separation anxiety disorder
- Inhibited temperament
- Neurobiology of other anxiety disorders
- Pharmacology of obsessive-compulsive disorders
- Psychopharmacology of other childhood anxiety disorders

Psychotic Disorders

- Childhood schizophrenia: positive and negative symptoms and disorganization symptoms
- Psychotic mood disorders
- Psychosis associated with medical conditions
- Neurobiology
- Psychopharmacology
- Side effects of antipsychotic medications: extrapyramidal, anticholinergic, antiadrenergic, tardive dyskinesia, metabolic
- Guidelines for the pharmacological treatment of psychotic disorders
- Relapse prevention

Attention-Deficit/Hyperactivity Disorder

- Differential diagnosis
- Neurobiology of ADHD
- Pharmacology of stimulants: immediate versus sustained release, generic, brand and typical dose information
- Guidelines for pharmacological treatment of ADHD including side effects and solutions
- Consequences of misdiagnosis of ADHD as an anxiety disorder, agitated disorder, pre-schizophrenia, bipolar disorder, or situational stress
- Alpha-2 adrenergic agonists used to treat ADHD
- Antidepressants used to treat ADHD
- Combined behavioral treatment and psychopharmacology

Autism Spectrum Disorders

- Diagnostic issues of pervasive developmental disorders
- Rett's disorder
- Childhood disintegrative disorder
- Pervasive development disorders
- Pathophysiology
- Psychopharmacology: serotonin medications, antipsychotics, beta-blockers, mood stabilizers, stimulants, opioid antagonists, oxytocin, miscellaneous agents

Miscellaneous Disorders: Diagnosis and Pharmacology

- Tic disorders and Tourette Syndrome
- Conduct disorder
- Anorexia nervosa
- Substance abuse: alcohol, stimulants, opiates, hallucinogens

Appendix: Patient and Caregiver Information Psychiatric Medications

PRIMARY AUTHOR

John D. Preston, Psy.D., ABPP, is Professor at Alliant International University, and has been Associate Clinical Professor at University of California, Davis. A Board Certified Neuropsychologist, he is the author of numerous texts concerning brain and behavior including Counseling Survivors of Traumatic Events, Child and Adolescent Psychopharmacology, Handbook of Clinical Psychopharmacology, and is co-editor of Empirically Validated Approaches to Psychotherapy. Dr. Preston received the Mental Health Association's President's Award for exceptional contributions to the mental health community.

An outstanding and inspiring speaker, Dr. Preston has given over 500 invited seminars to health professionals in North America and abroad. Participants commend his ability to communicate key insights and practical information with clarity, enthusiasm and warmth.